Neotigason (Acitretin)

Acitretin, the active ingredient in Neotigason, is a retinoid presented as an oral tablet for oral use. It is indicated for the management of severe plaque psoriasis, pustular psoriasis and certain forms of ichthyosis in adult patients. GNH USA supplies Neotigason as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Neotigason, a systemic retinoid, is employed in dermatologic disorders that involve abnormal keratinization. - Severe plaque psoriasis: reduces scaling, erythema and plaque thickness by normalising keratinocyte differentiation. - Pustular psoriasis: controls widespread pustular eruptions through anti‑inflammatory and keratinisation‑modulating effects. - Ichthyosis: improves skin barrier function and reduces hyperkeratosis by restoring normal epidermal cell turnover.

Acitretin may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Dry skin: increased epidermal dryness and scaling. - Cheilitis: inflammation and cracking of the lips. - Hair loss: temporary thinning of scalp hair. - Elevated liver enzymes: mild transaminase rise detected on routine labs. - Hyperlipidaemia: increase in serum triglycerides and cholesterol. - Headache: mild to moderate cephalic discomfort.

Serious or Rare Side Effects: - Severe hepatic toxicity: jaundice or hepatic failure requiring discontinuation. - Pancreatitis: acute abdominal pain with elevated pancreatic enzymes. - Depression or mood changes: new‑onset depressive symptoms. - Severe hypertriglyceridaemia: risk of pancreatitis. - Teratogenicity: congenital malformations if exposure occurs during pregnancy. - Bone changes: premature epiphyseal closure in adolescents.

Before initiating therapy, clinicians should assess several safety parameters and counsel patients on risk mitigation. - Pregnancy contraindication: avoid use in women of child‑bearing potential; effective contraception required for at least 3 years after discontinuation. - Liver function monitoring: obtain baseline and periodic liver enzyme tests. - Lipid profile monitoring: check fasting triglycerides and cholesterol before and during treatment. - Concomitant vitamin A: avoid combined use to prevent excess retinoid toxicity. - Severe hyperlipidaemia: contraindicated in patients with uncontrolled lipid disorders. - Store at ambient temperature: keep in the original pack, protect from moisture and light.

Acitretin can interact with several medicines, altering efficacy or safety.

Major Interactions (Avoid): - Tetracyclines: increased risk of intracranial hypertension. - Systemic vitamin A: additive teratogenic and toxicity risk. - Cholestyramine or colestipol: reduces acitretin absorption, decreasing effectiveness. - Oral contraceptives: may reduce contraceptive efficacy, increasing teratogenic risk. - Warfarin: potential alteration of INR and bleeding risk.

Moderate Interactions (Monitor Closely): - Methotrexate: additive hepatotoxicity; monitor liver enzymes. - Statins: possible exacerbation of lipid abnormalities. - Corticosteroids: enhanced anti‑inflammatory effects; watch for signs of excess. - Phototherapy: increased photosensitivity; advise sun protection. - Diuretics: may raise serum uric acid levels, risking gout.